allergytalk

Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the May-June 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed: Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria Please rate our podcast on Apple Podcasts!   Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the May-June 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed: Association of Allergy Specialty Care and Asthma Outcomes for Medicaid-Enrolled Children Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children Anaphylactic degranulation by mast cells requires the mobilization of inflammasome components   Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we are joined by Dr. Sarah Spreit, a Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of Allergy Watch. We will be reviewing the January/February 2025 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.   For information about CME credit, head over to http://education.acaai.org/allergytalk   To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch   Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed:   Persistent cat ownership and asthma in a longitudinal study of Puerto Rican youth   The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children – A pivotal phase III trial   Awareness and application of United States food allergy prevention guidelines among pediatricians and other clinicians   Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

The ACAAI FIT Committee leaders Dr. Kylie Jungles and Dr. Amber Hardeman invite the ACAAI Practice Management Committee chair Dr. Melinda Rathkopf to discuss advice on landing your first position. Keep listening as our experts talk about Narrowing Down Your Choices, Demystifying Contracts & Negotiation, Should I Have a Contract Lawyer in my Corner?, and When Can I Get Started?/Transition Planning.   For information about CME credit, head over to http://education.acaai.org/allergytalk Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org     ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

The ACAAI FIT Committee leaders Dr. Kylie Jungles and Dr. Amber Hardeman invite the ACAAI Practice Management Committee chair Dr. Melinda Rathkopf to discuss key points for FITs to keep in mind when beginning their job search. Topics include Choosing the Right Practice Setting, Creating a Job Search Game Plan, and Interviewing Like a Pro.   For information about CME credit, head over to http://education.acaai.org/allergytalk Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org     ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Welcome to a special episode of AllergyTalk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma & Immunology! On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients! We are joined by Michael S. Blaiss, MD, clinical professor of pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines.   Resources: FDA Drug Safety Communication on Cetirizine and Levocetirizine ACAAI Advice on Speaking Points Regarding FDA Alert   Previous articles describing this side effect: Unbearable Pruritus After Withdrawal of (Levo)cetirizine. Pruritus after discontinuation of cetirizine.

Today we are joined by Dr. Sarah Spriet, a Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of Allergy Watch. We will be reviewing the January/February 2025 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.   For information about CME credit, head over to http://education.acaai.org/allergytalk   To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch   Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed: A novel syndrome of silent rhinovirus-associated bronchoalveolitis in children with recurrent wheeze Effects of moderate- versus vigorous-intensity exercise training on asthma outcomes in adults Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we are joined by Dr. Iris Otani, an associate professor of medicine at UCSF and an assistant editor of Allergy Watch. We will be reviewing the November-December 2024 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.   For information about CME credit, head over to http://education.acaai.org/allergytalk   To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed: Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices. Forecasting daily total pollen concentrations on a global scale. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.   Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we are joined by Dr. Iris Otani, an associate professor of medicine at UCSF and an assistant editor of Allergy Watch. We will be reviewing the November-December 2024 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial. Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study. Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Welcome to Season Three of AllergyTalk!   Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.   For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch   Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed: The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry.  Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders.  Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant: Pharming, Kaleo Speaker: CSL, Takeda, Kaleo

Welcome to Season Three of Allergytalk! Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins.  Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.   Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant/Speaker: Kaleo Consultant: Allergy & Asthma Network, Pharming Speaker: CSL, Takeda  

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI   Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.   Learning Objective: After listening to this podcast episode, participants should be better able to: Employ strategies for long-term prophylaxis. References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022   Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia   Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva   This podcast miniseries is supported by a grant from Takeda.

Episode 2: Overcoming Barriers in HAE Treatment   Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI   This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.   Learning Objective: After listening to this podcast episode, participants should be better able to: Create effective treatment plans for their specific population (minority, rural, urban)   References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022   Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva   Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda   This podcast miniseries is supported by a grant from Takeda.

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed. Learning Objective: After listening to this podcast episode, participants should be better able to: Diagnose pediatric HAE accurately References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022 Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia   Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda   This podcast miniseries is supported by a grant from Takeda.

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! CRISPR Gene-Editing Therapy for Hereditary Angioedema Reviewed by Samantha knox CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975. New Peanut Allergy Rare After Peanut Introduction in Infants Reviewed by Sarah Spriet Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.   IgE to Food Allergens and Cardiovascular Mortality Reviewed by Gerry Lee IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.   Please rate our podcast on Apple podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Reviewed by Iris Otani Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839. Clinical Remission in a Real-World Severe Asthma Registry Reviewed by Tim Chow Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453. More Evidence Against Using Corticosteroids for Anaphylaxis Reviewed by Iris Otani Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113. Please rate our podcast on Apple podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma   Host: Gerald B. Lee, MD, FACAAI Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi   Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron   This podcast miniseries is supported by a grant from AstraZeneca.

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma   Host: Gerald B. Lee, MD, FACAAI Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity   Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   William C. Anderson III, MD, FACAAI Advisor: Genentech, Regeneron, Sanofi   Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi   This podcast miniseries is supported by a grant from AstraZeneca.

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 1: The Limitations of Bronchodilator Only Rescue Therapy   Host: Gerald B. Lee, MD, FACAAI Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity   Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   William C. Anderson III, MD, FACAAI Advisor: Genentech, Regeneron, Sanofi   Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron   This podcast miniseries is supported by a grant from AstraZeneca.

Welcome to Season Three of Allergytalk! Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Gut microbiota maturity mediates the protective effect of siblings on food allergy. Duration of skin prick test refractory period following food-induced allergic reactions. Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy